These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38667795)

  • 21. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
    Fernández-Teruel C; Lubomirov R; Fudio S
    J Clin Pharmacol; 2021 Sep; 61(9):1206-1219. PubMed ID: 33914350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
    Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
    Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
    Metaxas Y; Kahatt C; Alfaro V; Fudio S; Zeaiter A; Plummer R; Sessa C; Von Moos R; Forster M; Stathis A
    Invest New Drugs; 2022 Feb; 40(1):91-98. PubMed ID: 34453241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAF
    Zhang W; Mathisen M; Goodman GR; Forbes H; Song Y; Bertran E; Demidov L; Shin SJ
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):39-45. PubMed ID: 32602215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.
    Tachibana M; Matsuki S; Maekawa Y; Kuroda K; Shimizu T; Tsutsumi J; Ishizuka H
    Clin Transl Sci; 2023 Nov; 16(11):2153-2162. PubMed ID: 37705321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
    Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
    Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
    Paz-Ares L; Forster M; Boni V; Szyldergemajn S; Corral J; Turnbull S; Cubillo A; Teruel CF; Calderero IL; Siguero M; Bohan P; Calvo E
    Invest New Drugs; 2017 Apr; 35(2):198-206. PubMed ID: 27873130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
    Mu S; Tang Z; Novotny W; Tawashi M; Li TK; Ou Y; Sahasranaman S
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):391-399. PubMed ID: 31875923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study.
    Hu X; Hsieh CY; Zhang Y; Liu W; Xu S; Cai SX; Liu L; Zhang M; Shi H; Zhang H; Liu P; Li X; Xu P
    Br J Clin Pharmacol; 2023 Jun; 89(6):1767-1779. PubMed ID: 36458825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers.
    Zhang S; Jin S; Griffin C; Feng Z; Lin J; Venkatakrishnan K; Gupta N
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1044-1053. PubMed ID: 34145979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
    Lehr T; Staab A; Trommeshauser D; Schaefer HG; Kloft C
    Clin Pharmacokinet; 2010; 49(1):53-66. PubMed ID: 20000889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
    Quinn DI; Nemunaitis J; Fuloria J; Britten CD; Gabrail N; Yee L; Acharya M; Chan K; Cohen N; Dudov A
    Clin Pharmacokinet; 2009; 48(3):199-209. PubMed ID: 19385713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.
    Templeton IE; Thummel KE; Kharasch ED; Kunze KL; Hoffer C; Nelson WL; Isoherranen N
    Clin Pharmacol Ther; 2008 Jan; 83(1):77-85. PubMed ID: 17495874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study.
    Huang Y; Jia Y; Chen X; Wang C; Wang Y; Wang M; Wu P; Shen J
    Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):1005-1013. PubMed ID: 38053514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
    Venkatakrishnan K; Rader M; Ramanathan RK; Ramalingam S; Chen E; Riordan W; Trepicchio W; Cooper M; Karol M; von Moltke L; Neuwirth R; Egorin M; Chatta G
    Clin Ther; 2009; 31 Pt 2():2444-58. PubMed ID: 20110052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours.
    Vermunt MAC; de Weger VA; Janssen JM; Lopez-Yurda MI; Keessen M; Thijssen B; Rosing H; Huitema ADR; Beijnen JH; Marchetti S
    Drugs R D; 2021 Mar; 21(1):103-111. PubMed ID: 33464545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
    Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
    Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults.
    Cox DS; Van Eyck L; Pawlak S; Beckerman B; Linn C; Ginman K; Thay Cha Y; LaBadie RR; Shi H; Damle B
    Br J Clin Pharmacol; 2023 Sep; 89(9):2867-2876. PubMed ID: 37184075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction.
    Tapaninen T; Olkkola AM; Tornio A; Neuvonen M; Elonen E; Neuvonen PJ; Niemi M; Backman JT
    Clin Transl Sci; 2020 Mar; 13(2):345-351. PubMed ID: 31664782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.